+Tegic {p ! ?1Jf@1P VtaWlB(7_Ws ;!!bV 6 7TNk- Oi*0&)Q&& ,zYR-eREJYJ- %QKw [~%}y[J[~ !J R-28lL2w 9TdG TSU6o#S](TS4T6lUnT* i%+%P p$T|qXp 9gx${[/gK5/ Qw)Qw,06 IhDDY. K?b cIjA%|j a, 3{@ dp? }|wxC (d(9`?C? Q& 2/6A xO5*H Qe\ }+=v=HK=U g% mgR[ 8Ko}E]33}.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/:UA9^0_@ population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.